Skip to main content
    M

    MiMedx Group Inc (MDXG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    -0.03 (-0.93%)

    Market Cap: $468.42M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    MiMedx Group Inc (MDXG) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    MiMedx Group reported revenue of $418.63M for the fiscal year ended Dec 31, 2025, up 20.0% from the year before. That year, net income was $48.58M with a net margin of 11.6%, operating cash flow was $74.00M and free cash flow was $72.97M. The quarter ended Sep 30, 2026 had revenue of $62.28M and net income of -$8.68M.

    Revenue and Margins

    The operating margin was 15.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $221.71M, a compound annual rate of 7.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$418.63M+20.0%82.6%15.3%11.6%
    Dec 2024$348.88M+8.5%82.8%16.9%12.2%
    Dec 2023$321.48M+20.0%83.0%11.5%18.1%
    Dec 2022$267.84M+10.7%82.0%-5.5%-11.3%
    Dec 2021$242.02M-2.5%83.6%-2.9%-4.2%
    Dec 2020$248.23M-17.0%84.2%-18.3%-19.9%
    Dec 2019$299.25M-16.7%85.6%-7.1%-8.5%
    Dec 2018$359.11M+11.8%89.9%-1.1%-8.3%
    Dec 2017$321.14M+44.8%89.0%14.4%20.2%
    Dec 2016$221.71MN/A86.0%0.4%0.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 14.5% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$418.63M$348.88M$321.48M$267.84M$242.02M$248.23M$299.25M$359.11M$321.14M$221.71M
    Cost of revenue$73.01M$60.07M$54.63M$48.32M$39.63M$39.33M$43.08M$36.39M$35.22M$30.94M
    Gross profit$345.62M$288.81M$266.84M$219.53M$202.39M$208.90M$256.17M$322.73M$285.92M$190.77M
    Research and development$15.10M$12.34M$12.66M$12.70M$9.93M$11.71M$11.14M$15.77M$17.90M$14.34M
    Operating income$63.89M$58.87M$37.12M-$14.73M-$7.05M-$45.40M-$21.16M-$3.92M$46.22M$884.00K
    Net income$48.58M$42.42M$58.23M-$30.20M-$10.29M-$49.28M-$25.58M-$29.98M$64.73M$390.00K
    EBITDA$78.21M$64.34M$40.52M-$10.69M-$836.00K-$36.27M-$11.86M$2.94M$51.10M$6.17M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$62.28M$64.36M$58.99M$118.09M$113.72M$98.61M$88.20M$92.91M$84.06M$87.21M$84.71M$86.83M
    Gross profit$49.70M$44.38M$41.62M$99.04M$95.01M$79.92M$71.65M$76.00M$68.73M$72.35M$71.72M$72.99M
    Operating income-$11.70M-$18.47M-$16.05M$21.08M$22.19M$12.37M$8.25M$11.05M$11.16M$23.45M$13.20M$15.49M
    Net income-$8.68M-$14.84M-$10.86M$15.19M$16.75M$9.62M$7.02M$7.44M$8.10M$17.63M$9.26M$53.48M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $17.97M by $148.15M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$342.65M$263.92M$239.05M$171.43M$187.93M$202.03M$167.17M$122.84M$121.25M$117.27M
    Current assets$277.47M$191.89M$164.26M$134.20M$148.52M$160.62M$123.25M$74.05M$48.75M$59.47M
    Cash and equivalents$166.12M$104.42M$82.00M$65.95M$87.08M$95.81M$69.07M$45.12M$27.48M$30.32M
    Total liabilities$86.11M$70.81M$96.33M$96.92M$95.35M$110.61M$132.77M$73.19M$47.46M$69.21M
    Short-term debt$1.50M$1.00M$1.00M$1.44M$1.25M$1.18M$3.75M$0N/A$31.00K
    Long-term debt$16.47M$17.83M$48.10M$48.59M$48.13M$47.70M$61.91M$0N/A$2.00K
    Shareholder equity$256.55M$193.11M$142.72M-$17.99M$82.00K-$150.00K$34.40M$49.66M$73.80M$48.07M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$264.55M$281.00M$308.68M$342.65M$318.99M$291.11M$270.42M$263.92M$243.89M$230.18M$221.68M$239.05M
    Total liabilities$53.47M$65.00M$65.74M$86.11M$80.04M$74.48M$67.64M$70.81M$62.88M$62.14M$65.95M$96.33M
    Cash and equivalents$120.79M$135.84M$159.77M$166.12M$142.08M$118.87M$106.43M$104.42M$88.80M$69.04M$48.49M$82.00M
    Shareholder equity$211.08M$216.00M$242.94M$256.55M$238.95M$216.62M$202.78M$193.11M$181.01M$168.04M$155.73M$142.72M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.6% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$74.00M$66.20M$26.77M-$17.89M-$1.98M-$30.26M-$39.41M$35.80M$62.94M$23.85M
    Capital expenditures$1.03M$1.68M$1.99M$1.51M$3.22M$4.23M$1.75M$9.42M$5.13M$6.21M
    Free cash flow$72.97M$64.52M$24.79M-$19.41M-$5.20M-$34.49M-$41.16M$26.38M$57.81M$17.64M
    Dividends paidN/AN/A$997.00K$651.00K$1.44M$100.00MN/AN/AN/A$0
    Share repurchases$0$0$9.52M$0$0$7.47M$0$7.57M$68.26M$10.38M
    Investing cash flow-$6.89M-$9.58M-$2.15M-$2.66M-$3.40M-$4.55M$504.00K-$9.22M-$5.40M-$11.68M
    Financing cash flow-$5.41M-$34.20M-$8.57M-$580.00K-$3.35M$61.56M$62.86M-$8.93M-$60.39M-$8.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$3.92M-$10.02M$1.88M$24.96M$29.33M$14.42M$5.30M$18.78M$19.62M$21.81M$5.98M$10.26M
    Capital expenditures$166.00K$598.00K$570.00K$285.00K$192.00K$179.00K$377.00K$263.00K$171.00K$105.00K$1.14M$427.00K
    Free cash flow$3.75M-$10.61M$1.31M$24.67M$29.14M$14.24M$4.92M$18.52M$19.45M$21.71M$4.83M$9.83M
    Last 12 quarters

    Frequently Asked Questions About MDXG

    What is MiMedx Group's annual revenue?

    MiMedx Group reported revenue of $418.63M for the fiscal year ended Dec 31, 2025.

    How fast is MiMedx Group's revenue growing?

    Revenue was up 20.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 16.1%.

    Is MiMedx Group profitable?

    Yes. MiMedx Group reported net income of $48.58M for the fiscal year ended Dec 31, 2025, with a net margin of 11.6%.

    How much free cash flow does MDXG generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $74.00M minus capital expenditures of $1.03M produced free cash flow of $72.97M.

    How much debt does MiMedx Group have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $16.47M, short-term debt of $1.50M and cash and equivalents of $166.12M.